| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ACADACADIA Pharmaceuticals Inc. | 4.48B | 26.46 | 19.46 | 31.85% | 24.94% | 28.47% | 3.51% | 0.07 |
| JAZZJazz Pharmaceuticals plc | 9.87B | 162.43 | 18.78 | 6.12% | -8.86% | -9.31% | 13.66% | 1.51 |
| CPRXCatalyst Pharmaceuticals, Inc. | 2.75B | 22.35 | 17.06 | 23.49% | 37.63% | 23.64% | 8.71% | 0.00 |
| HRMYHarmony Biosciences Holdings, Inc. | 2.06B | 35.76 | 14.25 | 22.8% | 22.48% | 22.23% | 10.62% | 0.28 |
| ALKSAlkermes plc | 4.81B | 29.15 | 13.43 | -6.36% | 22.27% | 19.55% | 8.43% | 0.05 |
| PRTCPureTech Health plc | 437.45M | 18.10 | 9.05 | 44.98% | -495.91% | -8.53% | 0.05 | |
| LBRXLB Pharmaceuticals Inc Common Stock | 500.67M | 19.79 | -1.11 | |||||
| NMRANeumora Therapeutics, Inc. Common Stock | 363.67M | 2.14 | -1.40 | -178.79% | 0.01 |
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 240 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | -240 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 334.29K | 1.29M | 2.75M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 1.72M | 1.63M | 1.8M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 137.24K | 1.61M | 954.59K |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | -1.52M | -1.94M | 0 |
| Operating Income | -334.29K | -1.29M | -2.75M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -2.87% | -1.13% |
| EBITDA | -334.29K | -1.29M | -2.75M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -2.87% | -1.13% |
| D&A (Non-Cash Add-back) | 0 | 0 | 240 |
| EBIT | 0 | 0 | -51.11M |
| Net Interest Income | 0 | 1.55K | -50.81K |
| Interest Income | 0 | 1.55K | 2.13K |
| Interest Expense | 0 | 0 | 52.94K |
| Other Income/Expense | 8.56M | 9.31M | -48.41M |
| Pretax Income | 8.23M | 8.01M | -51.16M |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% |
| Net Income | 8.23M | 8.01M | -51.16M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | -0.03% | -7.38% |
| Net Income (Continuing) | 8.23M | 8.01M | -51.16M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | 0.25 | -0.64 | -7.85 |
| EPS Growth % | - | -3.56% | -11.27% |
| EPS (Basic) | 0.25 | -0.64 | -7.85 |
| Diluted Shares Outstanding | 32.67M | 32.67M | 6.52M |
| Basic Shares Outstanding | 32.67M | 32.67M | 6.52M |
| Dividend Payout Ratio | - | - | - |
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Total Current Assets | 797.2K | 1.21M | 1.13M |
| Cash & Short-Term Investments | 431.9K | 15.96K | 762.8K |
| Cash Only | 648.28K | 128.68K | 762.8K |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 39.55K | 60.9K | 41.75K |
| Days Sales Outstanding | - | - | - |
| Inventory | -39.55K | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 0 | 917.12K | 0 |
| Total Non-Current Assets | 255.25M | 257.73M | 5.49K |
| Property, Plant & Equipment | 0 | 0 | 5.49K |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 255M | 257.73M | 0 |
| Other Non-Current Assets | 248.65K | 0 | 0 |
| Total Assets | 256.22M | 258.93M | 1.13M |
| Asset Turnover | - | - | - |
| Asset Growth % | - | 0.01% | -1% |
| Total Current Liabilities | 68.7K | 14.27M | 12.1M |
| Accounts Payable | 36.89K | 1.63M | 562.35K |
| Days Payables Outstanding | - | - | 855.24K |
| Short-Term Debt | 0 | 685K | 10.45M |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | -63.06K | 11.8M | 968.51K |
| Current Ratio | 11.60x | 0.08x | 0.09x |
| Quick Ratio | 12.18x | 0.08x | 0.09x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 16.24M | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 16.24M | 0 | 0 |
| Total Liabilities | 19.58M | 14.27M | 12.1M |
| Total Debt | 0 | 685K | 10.45M |
| Net Debt | -648.28K | -128.68K | 9.71M |
| Debt / Equity | - | 0.00x | - |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | - | - | -51.98x |
| Total Equity | 236.65M | 244.66M | -10.97M |
| Equity Growth % | - | 0.03% | -1.04% |
| Book Value per Share | 7.24 | 7.49 | -1.68 |
| Total Shareholders' Equity | 236.65M | 244.66M | -10.97M |
| Common Stock | 255M | 258.55M | 46.13M |
| Retained Earnings | -18.36M | -13.9M | -57.46M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 361.06K |
| Minority Interest | 0 | 0 | 0 |
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Cash from Operations | -1.4M | -519.6K | -2.95M |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | 0.63% | -4.67% |
| Net Income | -1.86M | -24.49K | -51.16M |
| Depreciation & Amortization | 0 | 0 | 240 |
| Stock-Based Compensation | 332.07K | 221.29K | 317.88K |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -661.96K | 49.07M |
| Working Capital Changes | 129.74K | -54.44K | -1.17M |
| Change in Receivables | 100.05K | 0 | 107.62K |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 |
| Cash from Investing | -32.04K | 0 | -5.73K |
| Capital Expenditures | 0 | 0 | -5.73K |
| CapEx % of Revenue | - | - | - |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 254.97M | 0 | 0 |
| Cash from Financing | -1.63M | 1.17M | 2.35M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | -1.63M | 1.17M | 0 |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -839.17K | -519.6K | -2.95M |
| FCF Margin % | - | - | - |
| FCF Growth % | - | 0.38% | -4.68% |
| FCF per Share | -0.03 | -0.02 | -0.45 |
| FCF Conversion (FCF/Net Income) | -0.17x | -0.06x | 0.06x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Return on Equity (ROE) | 3.48% | 3.33% | -43.78% |
| Return on Invested Capital (ROIC) | - | -0.4% | -1.69% |
| Debt / Equity | - | 0.00x | - |
| Interest Coverage | - | - | -51.98x |
| FCF Conversion | -0.17x | -0.06x | 0.06x |
Psyence Biomedical Ltd. (PBM) grew revenue by 0.0% over the past year. Growth has been modest.
Psyence Biomedical Ltd. (PBM) reported a net loss of $25.5M for fiscal year 2023.
Psyence Biomedical Ltd. (PBM) has a return on equity (ROE) of -43.8%. Negative ROE indicates the company is unprofitable.
Psyence Biomedical Ltd. (PBM) had negative free cash flow of $1.1M in fiscal year 2023, likely due to heavy capital investments.